View a Transcript of the Podcast here

Discovery of High-Affinity Human PD-1 and LAG-3 Antibodies Using Novel Microfluidic and Molecular Genomic Methods

David S. Johnson, PhD, CEO, GigaGen

Cambridge Healthtech Institute’s Kent Simmons recently spoke with Dr. David Johnson, CEO of GigaGen, about his upcoming presentation “Discovery of High-Affinity Human PD-1 and LAG-3 Antibodies Using Novel Microfluidic and Molecular Genomic Methods”, to be delivered in the Engineering Antibodies meeting at the 2018 PEGS Boston. PEGS is scheduled for April 30 - May 4, 2018 in Boston, with the antibodies program set for May 2-3.

View a Transcript of the Podcast here

Development on Novel Therapeutic Antibodies for Cancer Derived from Single Human B Cells

Edward F. Patz, Jr., M.D., James and Alice Chen Professor, Radiology; Professor, Pharmacology and Cancer Biology, Radiology, Duke University Medical Center

Dr. Edward Patz outlines what he considers some of the greatest obstacles to developing novel antibodies from single human B cells, how he recognized a novel and unexpected target in lung cancer, the current status of the first novel antibody he developed, advice for people introducing novel antibody therapeutics in the clinical setting and exciting new developments emerging for antibodies derived from single human B cells.

Topics Include: Antibody therapeutics, Cancer Therapy, Autoantibodies, Single Human B Cells

View a Transcript of the Podcast here

Future Directions for HX-MS in Formulation Development and Similarity Assessment

David D. Weis, Ph.D., Associate Professor, Pharmaceutical Chemistry, University of Kansas

A podcast interview with PEGS speaker David Weis of the University of Kansas. Dr. Weis is speaking in the Biophysical Analysis of Biotherapeutics meeting, where he will give a presentation on the topic “Hydrogen Exchange Mass Spectrometry in Formulation Development and Similarity Assessment”

Topics Include: Analytical Ultracentrifugation (AUC), Assays for developability evaluation, Biophysical analysis of high concentration proteins, Biophysical assay qualification and validation, Characterization and Analysis of Particulates, Developability, Engineering solutions to biophysical liabilities, Field-Flow Fractionation (FFF), Formulation solutions to biophysical liabilities, Light Scattering, Low-field NMR, Mass spectrometry, Miniaturization of biophysical assays, Multiplexing and parallelization of biophysical analytical methods, Orthogonal methods, Predictive modeling for biophysical characteristics, Protein Formulation, Size exclusion chromatography, Spectroscopic methods for biophysical analysis, X-ray crystallography

View a Transcript of the Podcast here

New Technology on Multiplex ADA Isotyping

Shuangping Shi, Ph.D., Director, Biologics and Vaccines Bioanalytics, Merck Research Laboratories

JBiotherapeutic drugs such as monoclonal antibodies (mAbs) have the potential to induce immunogenicity; therefore, it is critical to perform an immunogenicity assessment to ensure drug efficacy and patient safety. In general, an immunogenicity assessment is performed in a multi-tiered approach: screening of anti-drug antibodies (ADA), confirmatory test, titer assessment, characterization of ADA for neutralizing drug activity and isotyping. The goal of our work is to develop multiplex approaches on various platforms including Meso Scale Discovery (MSD), Luminex and Delfia for ADA characterization.

View a Transcript of the Podcast here

Preventing Toxicity in CAR T Cell Therapy

Peter Emtage, Senior Vice President, Research, Cell Design Labs

Peter Emtage from Cell Design Labs recently spoke with CHI. He will be speaking at PEGS in the Preventing Toxicity in Immunotherapy conference on May 2nd, 2017. Cell Design Labs is working with small molecules to modulate CAR T cells, which would allow clinicians to monitor and prevent toxicity issues in cancer treatment.

Topics Include: Immunotherapy, CAR, T cell, Toxicity, Toxicity in immunotherapy, immuno oncology, immuno-oncology, cancer, cancer treatment, oncology, adoptive cellular therapies, immune-related adverse events, immune related adverse events

View a Transcript of the Podcast here

The Promise of Neoantigens for Personalized Cancer Vaccines

Philip M. Arlen, M.D., President and CEO, Precision Biologics, Inc.

Philip Arlen from Precision Biologics recently spoke with CHI. He will be speaking at PEGS in the Adoptive T Cell Therapy conference on May 3rd 2017. Precision Biologics is working with cancer vaccines to develop personalized cancer treatments that target tumors without damaging healthy human tissues.

Topics Include: neoantigens, cancer vaccines, vaccines, immunotherapy, CAR, t-cell, t cell, colorectal cancer, personalized diagnostics, personalized immunotherapies, tumor, cancer, cancer treatment, chimeric antigen receptor, clinical trials

View a Transcript of the Podcast here

Programming Proteins by Deep Sequencing and Design

Kent Simmons of CHI speaks with Dr. Tim Whitehead, Assistant Professor of Chemical Engineering and Materials Science at Michigan State University about his upcoming keynote presentation “Programming Proteins by Deep Sequencing and Design” at PEGS Boston 2017.

Topics Include: Podcast, PEGS, Protein Engineering, Next-Generation Sequencing, Protein Affinity